Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has disclosed its FY2025 consolidated revenue forecast of KRW 5.5705T (midpoint of the expected YoY growth range of +20% to +25%). The variance between the FY2024 revenue forecast and actual performance was 4.7%.
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: Outlook on Operating Results Based on Consolidated Financial Statements (Fair Disclosure)
- Forecast Period: FY2025 (Jan 1, 2025 – Dec 31, 2025)
- FY2025 Consolidated Operating Forecast (Unit: KRW 100 million):
- Revenue: KRW 55,705 hundred million (Midpoint applied from expected growth range of +20% to +25% YoY)
- Operating Profit / Profit Before Income Tax / Net Profit: Not stated (-)
- Basis of Forecast: Market outlook and business plans
- Difference Between FY2024 Forecast and Actual Results (Unit: KRW 100 million, %):
- Revenue: Forecast KRW 43,411 hundred million / Actual KRW 45,473 hundred million / Error Rate 4.7%
- Information Provision Details:
- Provider: IR Team
- Target Audience: Domestic and foreign investors, etc.
- Date & Time: January 22, 2025
- Other Important Details:
- The above forecast is forward-looking information based on business plans and actual results may differ depending on market conditions and economic environment.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring FY2025 Revenue Target Achievement and Future Earnings Filings
This disclosure provides notice of Samsung Biologics’ FY2025 consolidated revenue outlook via fair disclosure.
Tracking the actual performance against the guidance figure (KRW 5.5705T) throughout FY2025 quarterly and annual earnings releases is essential.
Relevant details can be verified in subsequent quarterly provisional operating results disclosures and periodic filings.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
